OptimizeRx (NASDAQ:OPRX - Get Free Report) will be posting its quarterly earnings results after the market closes on Wednesday, November 13th. Analysts expect OptimizeRx to post earnings of $0.06 per share for the quarter. OptimizeRx has set its FY 2024 guidance at EPS.Investors interested in participating in the company's conference call can do so using this link.
OptimizeRx (NASDAQ:OPRX - Get Free Report) last issued its quarterly earnings data on Thursday, August 8th. The company reported ($0.14) EPS for the quarter, topping the consensus estimate of ($0.25) by $0.11. The business had revenue of $18.81 million during the quarter, compared to analyst estimates of $20.47 million. OptimizeRx had a negative net margin of 21.53% and a negative return on equity of 5.97%. On average, analysts expect OptimizeRx to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.
OptimizeRx Stock Up 20.5 %
Shares of OPRX stock traded up $1.05 during mid-day trading on Wednesday, reaching $6.16. 217,655 shares of the company's stock traded hands, compared to its average volume of 127,427. OptimizeRx has a 12 month low of $5.04 and a 12 month high of $16.65. The company has a quick ratio of 3.07, a current ratio of 3.07 and a debt-to-equity ratio of 0.27. The company has a market cap of $112.86 million, a P/E ratio of -5.86 and a beta of 1.32. The company's 50-day moving average price is $6.98 and its 200-day moving average price is $9.20.
Analyst Upgrades and Downgrades
A number of research analysts recently weighed in on OPRX shares. B. Riley initiated coverage on shares of OptimizeRx in a research report on Thursday, July 25th. They set a "buy" rating and a $18.50 price objective on the stock. Royal Bank of Canada lowered their price objective on OptimizeRx from $17.00 to $14.00 and set an "outperform" rating on the stock in a research report on Friday, August 16th. Finally, Barclays lowered their price target on OptimizeRx from $15.00 to $11.00 and set an "equal weight" rating on the stock in a report on Monday, August 12th. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average price target of $14.50.
Check Out Our Latest Analysis on OPRX
About OptimizeRx
(
Get Free Report)
OptimizeRx Corporation, a digital health technology company, enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. It offers various tech-enabled marketing solutions through its Artificial Intelligence-generated Dynamic Audience and Activation Platform, which enables customers to execute traditional marketing campaigns on its proprietary digital point-of-care network, as well as dynamic marketing campaigns that optimize audiences in real time to increase the value of treatment information for healthcare professionals and patients in response to clinical care events.
Further Reading
Before you consider OptimizeRx, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and OptimizeRx wasn't on the list.
While OptimizeRx currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for December 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
